Patient characteristics
| Patient no.* . | Sex . | Age, y . | Time, y† . | WBC . | Stage‡ . | CD38, % . | β2M§ . | Cytogenetic . | Treatments|| . | IGHV status¶ . | CLL methylation# . | ZAP70 methylation call (<0.2)** . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 72 | 10 | 175 | 3 | 1 | 3.8 | NA | 0 | MU | HP | High |
| 2 | F | 79 | 4 | 112 | 4 | 1 | 11 | Normal | 1 | NA | NA | NA |
| 3 | M | 62 | 8 | 102 | 4 | 35 | 3.2 | 11q | 0 | U | LP | Low |
| 4 | F | 77 | 10 | 46 | 4 | 12 | 3 | NA | 0 | MU | IP | Low |
| 5 | M | 59 | 12 | 589 | 4 | 15 | 4.9 | Normal | 2 | NA | HP | High |
| 6 | M | 67 | 8 | 161 | 4 | 1 | 2.6 | 13q | 0 | NA | HP | High |
| 7 | M | 71 | 13 | 147 | 4 | 3 | 3.8 | 13q | 3 | NA | HP | Low |
| 8 | M | 67 | 4 | 103 | 4 | 1 | 5.4 | Normal | 1 | NA | NA | NA |
| 9 | M | 75 | 21 | 154 | 4 | 18 | 6.1 | NA | 0 | NA | NA | NA |
| 10 | F | 76 | 3 | 33 | 4 | 1 | 2.9 | NA | 0 | NA | NA | NA |
| 11 | M | 78 | 1 | 46 | 4 | 25 | 4.3 | NA | 0 | MU | NA | NA |
| 12 | F | 67 | 12 | 44 | 3 | 1 | 2.4 | 13q, 17p | 3 | NA | NA | NA |
| 13 | M | 58 | 4 | 36 | 2 | 1 | 2.2 | NA | 0 | NA | HP | High |
| 14 | F | 76 | 11 | 70 | 4 | NA | 4.3 | NA | 2 | NA | NA | NA |
| 15 | M | 62 | 14 | 20 | 2 | 1 | 2.1 | 13q | 5 | MU | HP | High |
| 16 | F | 82 | 11 | 75 | 4 | 1 | 4 | Normal | 0 | NA | HP | High |
| 17 | M | 76 | 12 | 38 | 4 | NA | 6 | t12 | 2 | NA | LP | Low |
| 18 | F | 79 | 3 | 147 | 3 | 1 | 6.4 | 17p | 3 | MU | HP | High |
| 19 | F | 81 | 3 | 94 | 4 | 3 | 4.5 | NA | 1 | NA | LP | Low |
| 20 | F | 66 | 24 | 74 | 4 | 1 | 3.5 | 13q | 3 | NA | LP | Low |
| 21 | M | 75 | 3 | 144 | 4 | NA | 6.1 | NA | 0 | NA | NA | NA |
| 22 | M | 85 | 6 | 237 | 3 | 1 | 2.2 | NA | 0 | MU | IP | Low |
| 23 | M | 55 | 2 | 99 | 2 | 1 | 3 | 13q | 0 | MU | IP | Low |
| 24 | F | 79 | 5 | 313 | 3 | 1 | 7.4 | 13q, 17p | 2 | U | LP | Low |
| 25 | F | 60 | 24 | 72 | 4 | 2 | 2.7 | 13q | 0 | NA | NA | NA |
| 26 | F | 73 | 10 | 146 | 4 | 1 | 5 | 13q | 1 | MU | IP | Low |
| 27 | F | 87 | 18 | 14 | 4 | 8 | 15.6 | t12 | 3 | NA | NA | NA |
| 28 | F | 57 | 1 | 112 | 4 | 0 | 5.1 | 13q, 17p | 2 | U | LP | Low |
| 29 | M | 68 | 12 | 59 | 2 | 1 | 3.6 | 13q | 1 | MU | HP | High |
| 30 | M | 66 | 14 | 85 | 2 | 1 | 2 | Normal | 1 | NA | HP | High |
| 31 | F | 64 | 4 | 36 | 4 | 16 | 4.1 | NA | 0 | NA | NA | NA |
| 32 | F | 56 | 5 | 147 | 2 | NA | 2.4 | NA | 0 | MU | HP | High |
| 33 | F | 76 | 7 | 22 | 2 | 2 | 3.5 | NA | 0 | U | IP | Low |
| 34 | M | 57 | 5 | 251 | 3 | NA | 2.9 | t12 | 1 | NA | HP | High |
| 35 | F | 73 | 9 | 296 | 4 | 1 | 5.6 | 13q | 2 | NA | LP | Low |
| 36 | M | 62 | 2 | 56 | 1 | 2 | 3.2 | NA | 0 | NA | NA | NA |
| 37 | M | 63 | 2 | 344 | 4 | NA | 3.4 | 17p | 1 | NA | NA | NA |
| 38 | M | 61 | 4 | 40 | 1 | 2 | 2.2 | NA | 0 | NA | NA | NA |
| 39 | F | 85 | 10 | 53 | 4 | 4 | 5.9 | 13q | 1 | NA | NA | NA |
| 40 | F | 56 | 6 | 240 | 2 | NA | 2.3 | NA | 0 | NA | NA | NA |
| 41 | F | 86 | 7 | 101 | 1 | 1 | 4 | NA | 0 | MU | NA | NA |
| 42 | M | 68 | 1 | 38 | 2 | 14 | 2.1 | NA | 0 | NA | NA | NA |
| 43 | M | 54 | 2 | 82 | 4 | 23 | 3 | t12 | 0 | NA | NA | NA |
| Patient no.* . | Sex . | Age, y . | Time, y† . | WBC . | Stage‡ . | CD38, % . | β2M§ . | Cytogenetic . | Treatments|| . | IGHV status¶ . | CLL methylation# . | ZAP70 methylation call (<0.2)** . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 72 | 10 | 175 | 3 | 1 | 3.8 | NA | 0 | MU | HP | High |
| 2 | F | 79 | 4 | 112 | 4 | 1 | 11 | Normal | 1 | NA | NA | NA |
| 3 | M | 62 | 8 | 102 | 4 | 35 | 3.2 | 11q | 0 | U | LP | Low |
| 4 | F | 77 | 10 | 46 | 4 | 12 | 3 | NA | 0 | MU | IP | Low |
| 5 | M | 59 | 12 | 589 | 4 | 15 | 4.9 | Normal | 2 | NA | HP | High |
| 6 | M | 67 | 8 | 161 | 4 | 1 | 2.6 | 13q | 0 | NA | HP | High |
| 7 | M | 71 | 13 | 147 | 4 | 3 | 3.8 | 13q | 3 | NA | HP | Low |
| 8 | M | 67 | 4 | 103 | 4 | 1 | 5.4 | Normal | 1 | NA | NA | NA |
| 9 | M | 75 | 21 | 154 | 4 | 18 | 6.1 | NA | 0 | NA | NA | NA |
| 10 | F | 76 | 3 | 33 | 4 | 1 | 2.9 | NA | 0 | NA | NA | NA |
| 11 | M | 78 | 1 | 46 | 4 | 25 | 4.3 | NA | 0 | MU | NA | NA |
| 12 | F | 67 | 12 | 44 | 3 | 1 | 2.4 | 13q, 17p | 3 | NA | NA | NA |
| 13 | M | 58 | 4 | 36 | 2 | 1 | 2.2 | NA | 0 | NA | HP | High |
| 14 | F | 76 | 11 | 70 | 4 | NA | 4.3 | NA | 2 | NA | NA | NA |
| 15 | M | 62 | 14 | 20 | 2 | 1 | 2.1 | 13q | 5 | MU | HP | High |
| 16 | F | 82 | 11 | 75 | 4 | 1 | 4 | Normal | 0 | NA | HP | High |
| 17 | M | 76 | 12 | 38 | 4 | NA | 6 | t12 | 2 | NA | LP | Low |
| 18 | F | 79 | 3 | 147 | 3 | 1 | 6.4 | 17p | 3 | MU | HP | High |
| 19 | F | 81 | 3 | 94 | 4 | 3 | 4.5 | NA | 1 | NA | LP | Low |
| 20 | F | 66 | 24 | 74 | 4 | 1 | 3.5 | 13q | 3 | NA | LP | Low |
| 21 | M | 75 | 3 | 144 | 4 | NA | 6.1 | NA | 0 | NA | NA | NA |
| 22 | M | 85 | 6 | 237 | 3 | 1 | 2.2 | NA | 0 | MU | IP | Low |
| 23 | M | 55 | 2 | 99 | 2 | 1 | 3 | 13q | 0 | MU | IP | Low |
| 24 | F | 79 | 5 | 313 | 3 | 1 | 7.4 | 13q, 17p | 2 | U | LP | Low |
| 25 | F | 60 | 24 | 72 | 4 | 2 | 2.7 | 13q | 0 | NA | NA | NA |
| 26 | F | 73 | 10 | 146 | 4 | 1 | 5 | 13q | 1 | MU | IP | Low |
| 27 | F | 87 | 18 | 14 | 4 | 8 | 15.6 | t12 | 3 | NA | NA | NA |
| 28 | F | 57 | 1 | 112 | 4 | 0 | 5.1 | 13q, 17p | 2 | U | LP | Low |
| 29 | M | 68 | 12 | 59 | 2 | 1 | 3.6 | 13q | 1 | MU | HP | High |
| 30 | M | 66 | 14 | 85 | 2 | 1 | 2 | Normal | 1 | NA | HP | High |
| 31 | F | 64 | 4 | 36 | 4 | 16 | 4.1 | NA | 0 | NA | NA | NA |
| 32 | F | 56 | 5 | 147 | 2 | NA | 2.4 | NA | 0 | MU | HP | High |
| 33 | F | 76 | 7 | 22 | 2 | 2 | 3.5 | NA | 0 | U | IP | Low |
| 34 | M | 57 | 5 | 251 | 3 | NA | 2.9 | t12 | 1 | NA | HP | High |
| 35 | F | 73 | 9 | 296 | 4 | 1 | 5.6 | 13q | 2 | NA | LP | Low |
| 36 | M | 62 | 2 | 56 | 1 | 2 | 3.2 | NA | 0 | NA | NA | NA |
| 37 | M | 63 | 2 | 344 | 4 | NA | 3.4 | 17p | 1 | NA | NA | NA |
| 38 | M | 61 | 4 | 40 | 1 | 2 | 2.2 | NA | 0 | NA | NA | NA |
| 39 | F | 85 | 10 | 53 | 4 | 4 | 5.9 | 13q | 1 | NA | NA | NA |
| 40 | F | 56 | 6 | 240 | 2 | NA | 2.3 | NA | 0 | NA | NA | NA |
| 41 | F | 86 | 7 | 101 | 1 | 1 | 4 | NA | 0 | MU | NA | NA |
| 42 | M | 68 | 1 | 38 | 2 | 14 | 2.1 | NA | 0 | NA | NA | NA |
| 43 | M | 54 | 2 | 82 | 4 | 23 | 3 | t12 | 0 | NA | NA | NA |
β2M, β2-microglobulin; F, female; HP, highly programmed CLL; IP, intermediate-programmed CLL; LP, low-programmed CLL; M, male; MU, mutated; NA, not available; U, unmutated; WBC, white blood cell count.
Corresponding patient numbers are maintained throughout this manuscript.
Time since diagnosis.
Rai stage: 0, lymphocytosis; I, with adenopathy; II, with hepatosplenomegaly; III, with anemia; IV, with thrombocytopenia.
Normal range is 0.6 to 2.3 µg/mL.
Including alkylator-, fludarabine-, high-dose glucocorticoid-, and/or antibody-based treatments, indicated treatments were stopped at least 3 months prior to time of analysis.
IGVH mutation status.
DNA methylation.
ZAP70 CpG+223 methylation, <0.2 = low, >0.2 = high.